1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会

汇添富基金11-28 08:11

消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。市场热门ETF方面，截至11月25日，医药ETF（159929）最新份额18.22亿份，最新规模23.61亿元，保持基金上市以来高位！估值方面，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-28 08:11","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2486387128","market":"sh","top_or_hot":-1,"title":"1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会","media":"汇添富基金","content":"<div>\n<p>消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。市场热门ETF方面，截至11月25日，医药ETF（159929）最新份额18.22亿份，最新规模23.61亿元，保持基金上市以来高位！估值方面，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-28 08:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b><strong>汇添富基金</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。市场热门ETF方面，截至11月25日，医药ETF（159929）最新份额18.22亿份，最新规模23.61亿元，保持基金上市以来高位！估值方面，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600420","symbol_name":"国药现代","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","article_id":"2486387128","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","pubTimestamp":1732752682,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","600055":"万东医疗","600056":"中国医药","600062":"华润双鹤","600079":"人福医药","600080":"金花股份","600085":"同仁堂","600129":"太极集团","600161":"天坛生物","600196":"复星医药","600200":"江苏吴中","600211":"西藏药业","600252":"中恒集团","600276":"恒瑞医药","600285":"羚锐制药","600329":"达仁堂","600332":"白云山","600351":"亚宝药业","600380":"健康元","600420":"国药现代","600422":"昆药集团","600436":"片仔癀","600488":"津药药业","600511":"国药股份","600521":"华海药业","600529":"山东药玻","600535":"天士力","600566":"济川药业","600572":"康恩贝","600721":"百花医药","600739":"辽宁成大","600763":"通策医疗","600771":"广誉远","600851":"海欣股份","600867":"通化东宝","600976":"健民集团","600998":"九州通","601607":"上海医药","603087":"甘李药业","603108":"润达医疗","603127":"昭衍新药","603233":"大参林","603259":"药明康德","603301":"振德医疗","603309":"维力医疗","603367":"辰欣药业","603392":"万泰生物","603439":"贵州三力","603456":"九洲药业","603538":"美诺华","603567":"珍宝岛","603590":"康辰药业","603658":"安图生物","603707":"健友股份","603858":"步长制药","603882":"金域医学","603896":"寿仙谷","603939":"益丰药房","605177":"东亚药业","605199":"葫芦娃","688029":"南微医学","688046":"药康生物","688050":"爱博医疗","688062":"迈威生物","688067":"爱威科技","688073":"毕得医药","688076":"诺泰生物","688085":"三友医疗","688091":"上海谊众","688105":"诺唯赞","688114":"华大智造","688117":"圣诺生物","688137":"近岸蛋白","688139":"海尔生物","688161":"威高骨科","688163":"赛伦生物","688166":"博瑞医药","688176":"亚虹医药","688177":"百奥泰","688180":"君实生物","688189":"南新制药","688192":"迪哲医药","688193":"仁度生物","688198":"佰仁医疗","688202":"美迪西","688212":"澳华内镜","688221":"前沿生物","688222":"成都先导","688235":"百济神州","688247":"宣泰医药","688266":"泽璟制药","688271":"联影医疗","688276":"百克生物","688278":"特宝生物","688298":"东方生物","688301":"奕瑞科技","688315":"诺禾致源","688321":"微芯生物","688331":"荣昌生物","688336":"三生国健","688351":"微电生理","688356":"键凯科技","688373":"盟科药业","688382":"益方生物","688389":"普门科技","688428":"诺诚健华","688443":"智翔金泰","688488":"艾迪药业","688506":"百利天恒","688520":"神州细胞","688566":"吉贝尔","688575":"亚辉龙","688578":"艾力斯","688581":"安杰思","688617":"惠泰医疗","688626":"翔宇医疗","688656":"浩欧博","688658":"悦康药业","688670":"金迪克","688687":"凯因科技","688690":"纳微科技","688767":"博拓生物","BK0096":"民营医院","BK0185":"二线龙头","BK0012":"证金概念","BK0188":"融资融券","BK0028":"国家队","BK0070":"员工持股","BK0239":"医药制造"},"translate_title":"From January to October, medical insurance overall income grew steadily, institutions: The reversal of the pharmaceutical market outlook stems from three major opportunities","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600055":0.9,"600056":0.9,"600062":0.9,"600079":0.9,"600080":0.9,"600085":0.9,"600129":0.9,"600161":0.9,"600196":0.9,"600200":0.9,"600211":0.9,"600252":0.9,"600276":0.9,"600285":0.9,"600329":0.9,"600332":0.9,"600351":0.9,"600380":0.9,"600420":0.9,"600422":0.9,"600436":0.9,"600488":0.9,"600511":0.9,"600521":0.9,"600529":0.9,"600535":0.9,"600566":0.9,"600572":0.9,"600721":0.9,"600739":0.9,"600763":0.9,"600771":0.9,"600851":0.9,"600867":0.9,"600976":0.9,"600998":0.9,"601607":0.9,"603087":0.9,"603108":0.9,"603127":0.9,"603233":0.9,"603259":0.9,"603301":0.9,"603309":0.9,"603367":0.9,"603392":0.9,"603439":0.9,"603456":0.9,"603538":0.9,"603567":0.9,"603590":0.9,"603658":0.9,"603707":0.9,"603858":0.9,"603882":0.9,"603896":0.9,"603939":0.9,"605177":0.9,"605199":0.9,"688029":0.9,"688046":0.9,"688050":0.9,"688062":0.9,"688067":0.9,"688073":0.9,"688076":0.9,"688085":0.9,"688091":0.9,"688105":0.9,"688114":0.9,"688117":0.9,"688137":0.9,"688139":0.9,"688161":0.9,"688163":0.9,"688166":0.9,"688176":0.9,"688177":0.9,"688180":0.9,"688189":0.9,"688192":0.9,"688193":0.9,"688198":0.9,"688202":0.9,"688212":0.9,"688221":0.9,"688222":0.9,"688235":0.9,"688247":0.9,"688266":0.9,"688271":0.9,"688276":0.9,"688278":0.9,"688298":0.9,"688301":0.9,"688315":0.9,"688321":0.9,"688331":0.9,"688336":0.9,"688351":0.9,"688356":0.9,"688373":0.9,"688382":0.9,"688389":0.9,"688428":0.9,"688443":0.9,"688488":0.9,"688506":0.9,"688520":0.9,"688566":0.9,"688575":0.9,"688578":0.9,"688581":0.9,"688617":0.9,"688626":0.9,"688656":0.9,"688658":0.9,"688670":0.9,"688687":0.9,"688690":0.9,"688767":0.9},"content_text":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。市场热门ETF方面，截至11月25日，医药ETF（159929）最新份额18.22亿份，最新规模23.61亿元，保持基金上市以来高位！估值方面，当前医药ETF（159929）标的指数估值性价比高，具有投资吸引力。截至11月25日，PE-TTM为29.17，近10年分位点26.03%，意味着估值已低于10年内 74%的时间区间，中长期投资价值显著！【机构火线点评医药后市：2025轻装上阵，反转源于三大机会】国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。从前三季度业绩表现看，A股医药板块初步止住收入利润下滑势头，幅度有所收窄，仍处于筑底过程中。但随着老龄化持续、居民医药消费稳定扩张，以及行业诊疗量持续恢复，医药的长期成长逻辑依然清晰，整体基本盘稳定。同时医药分红和股息水平持续上升，红利属性增强。2025年，国金证券认为医药板块的核心投资机会将围绕三大逻辑：（1）创新出海：海外BD持续开花结果，国内创新商业化兑现带来业绩改善。（2）需求复苏：近年来由于集采控费压力和消费环境变化，部分品种和细分赛道增速回落，企业、渠道和终端备货库存均处于低水平，未来如院内和消费医疗需求改善，可能带来业绩提振。（3）政策预期反转：行业趋于规范，价格趋于合理，收缩性政策比重下降，支持鼓励性政策崭露头角。基于创新出海、需求复苏、政策预期反转三大边际变化，看好医药赛道2025年轻装上阵，实现反转。落实到赛道和板块选择上，将上述三大逻辑映射到两类机会：（1）自上而下，看好创新药和仿创药的赛道性机会（出海创新+政策反转）。（2）自下而上，看好器械、中药、药店、消费医疗服务等领域中的个股景气度反转机会（需求复苏+政策反转）。【机构：医保局积极推进商业健康保险发展，医保数据共享助力市场快速增长】方正证券表示，推动“医保+商保”一体化发展，进一步完善多层次医疗保障体系。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。会议指出，全国统一医保平台和大数据是重要的公共资源，应坚持公益性和公平性，同时注重经济性、安全性和可持续性。通过赋能商保机构，国家医保局希望进一步推动商业健康保险与基本医保的错位发展，以支持医药创新并充分保障人民群众的多元保障需求。此次会议强调了国家医保局对医保平台数据赋能商业健康保险发展的重视，以及对推动健康保险发展的决心。通过医保平台数据的赋能，商保机构可以更好地利用大数据进行产品设计和精算定价，从而提升服务质量和市场竞争力。医保数据共享作为推动商业健康保险发展的关键因素，或将逐步改变我国医疗保障服务的格局。多个城市如大连、南京和济南等地开展了医保和商保一站式结算的试点，其中上海在2024年9月底实现了两家商保公司与1家公立医院的医保+商保一站式结算。通过数据共享和流程优化，商业保险公司在核保、理赔和产品设计等方面实现了跨越式提升，特别是在健康险方面，受益于更精细化的精算定价和更高效的理赔服务。过去十年，我国商业健康险保费收入年均复合增长率显著，但发展水平相比发达国家还存在较大差距，2030年市场规模有望超过2万亿元。目前我国商业健康保险在国家医疗总费用中的占比仍然较低，仅为3.3%，远未满足公众对医疗保障的需求。发达国家的商业健康保险在医疗支出中占比显著更高，如法国为12%，英国为16%，澳大利亚为26.8%，韩国为37%，202年我国健康保险密度为640.93元/人，健康保险深度从2009年的0.16%增长至2023年的0.72%，CAGR为10.55%。方正证券认为，我国医疗保障体系目前最接近德国的社会医疗保险模式，根据目前实际发展情况判断，按照2030年达到德国的保险深度1.19%。假设2024-2030年GDP保持5%的复合增速，保守估计2030年我国健康险保费规模将增长至21107.81亿元，CAGR为12.89%。【看好医药板块行情，重点关注医药ETF（159929）】资料显示，医药ETF（159929）所跟踪的中证医药卫生指数（000933）全面覆盖医药板块细分领域。数据显示，截至2024年11月25日，中证医药卫生指数（000933）前十大权重股分别为恒瑞医药、药明康德、片仔癀、云南白药、新和成、上海莱士、长春高新、智飞生物、复星医药、泰格医药，前十大权重股合计占比51.78%。风险提示：基金有风险，投资需谨慎。投资人应当仔细阅读《基金合同》、《招募说明书》及《产品资料概要》等法律文件以详细了解产品信息。医药ETF为较高风险等级（R4）产品，适合经客户风险等级测评后结果为进取型（C4）及以上的投资者。标的指数并不能完全代表整个股票市场。标的指数成份股的平均回报率与整个股票市场的平均回报率可能存在偏离。文中提及个股仅为指数成份股客观展示列举，本文出现信息只作为参考，投资人须对任何自主决定的投资行为负责。本文中的任何观点、分析及预测不构成对阅读者任何形式的投资建议。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486387128"}